Nailike (olverembatinib) / Ascentage Pharma, Innovent Biologics, Takeda - LARVOL DELTA

Overcoming Multidrug Resistance in Cancer Cells Targeting ABC Transporter ABCB1 with Tyrosine Kinase Inhibitor: Olverembatinib. (PubMed, Exp Cell Res) - "Non-cytotoxic concentrations of olverembatinib significantly increased the sensitivity of ABCB1-overexpressing cells to paclitaxel and vincristine. Additionally, olverembatinib activated the ATPase activity of ABCB1 in a concentration-dependent manner and exhibited potent binding affinity to ABCB1 in docking simulations. These findings suggest that olverembatinib holds promise as a potent reversal agent for MDR, paving the way for its integration into novel combination chemotherapy regimens to improve cancer treatment outcomes."

Journal • Oncology • ABCB1

Targeting relapsed/refractory and MRD + Ph + ALL: olverembatinib-venetoclax bridging enhances allo-HSCT outcome​. (PubMed, Ann Hematol) - "With a median follow-up of 856-day post-HSCT, the 2-year overall survival and relapsed free survival rates was 88.2 ± 7.8% and 79.4 ± 10.9%, respectively. The findings of this study suggest that in Ph + ALL patients with disease recurrence and persistent MRD positivity, olverembatinib-venetoclax regimen showed a high molecular response rate and was well-tolerated in MRD clearance bridged to allo-HSCT."

Journal • Bone Marrow Transplantation • Hematological Disorders • ABL1 • BCR

Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor (ASH 2025) - "Specifically, dasatinib was administered to four patients, while olverembatinib for three patients...Prophylaxis for graft-versus-host disease (GVHD) routinely included cyclosporine A and mycophenolate mofetil, with or without methotrexate... Prompt HSCT for de novo CML-BP, combined with early TKI maintenance post-transplantation, appears to contribute to effective disease management. Additionally, unrelated cord blood donors seem to provide a viable source for transplantation. Furthermore, olverembatinib has demonstrated favorable safety and efficacy profiles both pre- and post-transplantation."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pediatrics • Transplantation • ABL1

Pathological feature in chronic myeloid leukemia patients with proteinuria receiving olverembatinib therapy (ASH 2025) - "Proteinuria appears to persist throughout olverembatinib therapy despite optimal therapeutic management. These preliminary findings require validation through future studies with larger sample size."

Clinical • Chronic Myeloid Leukemia • Diabetes • Dyslipidemia • Glomerulonephritis • Hematological Malignancies • Hypertension • Hypertriglyceridemia • Leukemia • Lupus Nephritis • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

Efficacy and safety of pegylated interferon alfa-2b combined with tyrosine kinase inhibitors in chronic Phase chronic myeloid leukemia patients with TKI resistance or intolerance (ASH 2025) - "Median follow-up was 72 weeks (range 24-96).Prior TKIs included imatinib, nilotinib, dasatinib, flumatinib,and olverembatinib.By June 30,2025.Sixteen, fourteen, ten, and eight patients completed therapy at weeks 24,48,72,and 96,respectively.Nine patients discontinued treatment due to adverse events.Molecular responses:Week 24: MMR 37.5% (6/16),DMR 6.3%(1/16),Week 48:MMR57.1% (8/14); Week 72: MMR40.0% (4/10); DMR 30.0% (3/10); Week 96: MMR 50.0% (4/8),DMR 25.0% (2/8).Safety:The most common AEs were flu-like symptoms and hematologic toxicities (predominantly grade 1-2).Dose reductions or extended dosing intervals (up to q2 weeks) of PEG IFNα-2b were implemented to manage AEs. Conclusion PEG IFNα-2b combined with TKIs significantly reduces BCR::ABL1 transcript levels, enabling patients with TKI-resistant or intolerant chronic-phase chronic myeloid leukemia (CP-CML) to achieve major molecular response (MMR) and even deep molecular response (DMR), with a favorable safety..."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • IFNA1

Overcoming asciminib resistance by targeting compound BCR::ABL1 mutations in chronic myeloid leukemia (ASH 2025) - "Selected candidate compounds demonstrating efficacy were validated across a panel of CML models, including Ba/F3 cells expressing wild-type BCR::ABL1, the T315I mutant (Ba/F3 T315I), and compound mutations (Ba/F3 PR: Y253H, E255K, and T315I), as well as K562 cells and their drug-resistant derivatives, K562 imatinib-resistant (K562 IR) and K562 ponatinib-resistant (K562 PR). CML cells with compound BCR::ABL1 mutations exhibited resistance to asciminib and, in part, to ponatinib, while bortezomib and selinexor retained efficacy in these resistant cells. Olverembatinib effectively suppressed proliferation and induced apoptosis in ABL TKI-resistant CML cells. The combination of olverembatinib and selinexor synergistically induced apoptosis and suppressed proliferation, offering a promising approach for overcoming TKI-resistant CML with compound mutations."

IO biomarker • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • CASP3 • CASP7

Updated Results from a Phase 1b study of olverembatinib (HQP1351) combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/refractory Philadelphia Chromosome–Positive acute lymphoblastic leukemia (ASH 2025) - P1 | "Patients received olverembatinib monotherapy (40 mg adult-equivalent dose [AED], every other day, days 1–14), followed by combination therapy with lisaftoclax (200, 400, or 600 mg AED daily, with 3-day dose ramp-up) and dexamethasone (6 mg/m²/day, days 15–42). Importantly, these outcomes were achieved without intensive chemotherapy or immunotherapy, highlighting this novel combination as an effective orally active and chemotherapy-free treatment option for this high-risk pediatric population. The study is ongoing for further efficacy and safety assessments and regimen optimization."

Clinical • P1 data • Acute Lymphocytic Leukemia • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia • Neutropenia • Pediatrics • Thrombocytopenia • ABL1

Multitarget kinase inhibitor olverembatinib is active and synergizes with BTK inhibitor acalabrutinib in preclinical models of Mantle Cell Lymphoma (ASH 2025) - "Conclusions In MCL preclinical models, olverembatinib is effective and synergizes with acalabrutinib to promote antitumor effects. These findings provide a scientific rationale for further clinical evaluation of olverembatinib and its combination with BTK inhibitors for the treatment of patients with MCL."

Preclinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • CASP3 • CDK4 • SYK

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study (ASH 2025) - "Among the frontline TKIs, the first-generation TKI imatinib has the highest usage rate(45.3%), followed by the second-generation TKIs dasatinib (32.3%) and flumatinib (8.7%). 4.8% of patientsreceived frontline olverembatinib treatment...Patients with ACAs have theworst prognosis compared to those with normal karyotype and Ph alone karyotype, and the impact isless significant under the allogeneic transplantation model. A complex karyotype is an independentunfavorable factor that significantly impacts the prognosis."

IO biomarker • Retrospective data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • ABL1 • BCR • RUNX1 • SETD2

Dynamic mutational evolution and transcriptomic remodeling on 3rd-generation TKI therapy in TKI-resistant patients with chronic myeloid leukemia (ASH 2025) - "Background Third-generation tyrosine kinase inhibitors (3G-TKIs), olverembatinib and ponatinib,improved outcomes for patients with resistant chronic myeloid leukemia (CML). Conclusions Our integrative longitudinal analyses revealed that 3G-TKI therapy induced divergentmolecular trajectories in CML: durable responses were defined by mutation clonal clearance,LSCs suppression and immune activation, whereas resistance was driven by persistent or expandingmutation clones (e.g., ASXL1G646Wfs*12, RUNX1 and PHF6), sustained stemness, and immune-cold states. Transcriptomic remodeling provided a powerful early indicator of therapeutic failure and supportsdynamic molecular monitoring to guide personalized therapy."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • ASXL1 • IFNA1 • PHF6 • RUNX1 • TNFA

Clinical and molecular features associated with glucolipid metabolic disorders and cardio-/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy (ASH 2025) - "22 (13%) patients experienced imatinib failure only; 50 (30%), imatinib,dasatinib and/or flumatinib therapy failure; and 95 (57%) had a history of nilotinib exposure. Higher total cholesterol, more priorTKI-therapy lines, particularly prior nilotinib exposure, the presence of ASXL1, FAT4 and/or TET2mutations were the independent predictors for glucolipid metabolic disorders, CCVAEs andarterial/venous occlusive events. These clinical and molecular features may guide early risk identificationand targeted surveillance."

Adverse events • Clinical • Cerebral Hemorrhage • Chronic Myeloid Leukemia • Congestive Heart Failure • Diabetes • Dyslipidemia • Heart Failure • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Metabolic Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • ABL1 • ASXL1 • FAT4 • TET2

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study (ASH 2025) - P1 | "35(66%) ptsreceived ≥ 3 prior TKIs; 24(45%) pts previously received ponatinib, olverembatinib, asciminib, and/or HS-10382 (STAMP inhibitor). Our study demonstrated that TGRX-678 achieved strong efficacy in patients with T315I-mutated CML in chronic or accelerated phase, with no clear dose–response relationship observed. Theseresults suggest that lower doses of TGRX-678 may offer comparable efficacy with potentially improvedsafety, particularly in heavily pretreated patients harboring T315I mutations."

Clinical • P1 data • Chronic Myeloid Leukemia • Diabetes • Dyslipidemia • Hypertriglyceridemia • Leukopenia • Metabolic Disorders • Neutropenia • Thrombocytopenia • ABL1

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML (ASH 2025) - P1 | "Herewe report initial results from the ongoing Phase 1 study of TERN-701 in pts with previously treated CML-CP. CARDINAL (NCT06163430) is an ongoing, open-label, two-part, global, multicenter Phase 1study in pts ≥18 years old with BCR::ABL1-positive CML-CP (with or without T315I mutation and withoutmyristoyl binding pocket mutations) previously treated with ≥1 prior second-generation (2G) TKI(bosutinib, dasatinib, or nilotinib)...Baseline characteristics included: median 3 prior TKIs (range: 1‒6); 35% had ≥4 prior TKIs; 36% had prior asciminib; 25% had prior ponatinib and/or investigational TKI(olverembatinib/ELVN-001); 56% had baseline BCR::ABL1>1%, with 44% having baseline BCR::ABL1>10%; and 13% with BCR::ABL1 mutations (9% T315I, 4% F317L)... TERN-701 demonstrated encouraging safety/tolerability and efficacy in a heavily pre-treatedpatient population with CML-CP previously treated with approved 1G/2G TKIs, ponatinib, asciminib, andother investigational,..."

Clinical • P1 data • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Thrombocytopenia

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations (ASH 2025) - P2 | "Introduction This was a multicenter, randomized, registrational phase 2 study to assess efficacy and safety ofolverembatinib vs. BAT in pts with CML-CP resistant and/or intolerant to three TKIs (imatinib [I]), dasatinib[D], nilotinib [N]) in China...Pts were randomized 2:1 to olverembatinib (40 mg QOD) or the BAT arm: TKIs (I, D, or N),interferon, hydroxyurea, and/or homoharringtonine by investigator choice...Olverembatinib was more efficacious andbetter tolerated than BAT in treating these pts (including those without T315I mutations). Internal study(CT.gov) numbers: HQP1351CC203 (NCT04126681)."

Clinical • P2 data • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Neutropenia • Thrombocytopenia • ABL1

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML) (ASH 2025) - P2 | "Twelve (25.5%) pts hadreceived imatinib as first-line, and 35 (74.5%) had been treated with a second-generation TKI, includingdasatinib (n = 7, 14.9%), nilotinib (n = 13, 27.7%), or flumatinib (n = 15, 31.9%), as first-line. Olverembatinib-related SAEs included platelet count decreased (6.4%) and anemia,myelosuppression, and pyrexia (2.1% each). No deaths were reported.ConclusionsOlverembatinib may provide a viable second-line treatment option for pts with CP-CML, especially thosewith disease failing first-line second-generation TKIs."

Clinical • Cardiovascular • Chronic Myeloid Leukemia • Hypertension • Neutropenia • Thrombocytopenia • ABL1 • BCR

The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, controll trial (ASH 2025) - "A higher proportion of efficacy in patients switching to olverembatinib treatment thanthose remained on treatment and continued to derive benefit over time, supporting olverembatinib mayas a standard of care for patients with CML-CP previously treated with ≥2 TKIs. Olverembatinib also canimprove the AEs relatived to prior TKI therapy and maybe a valuable therapeutic option for CML-CPpatients. KeywordOlverembatinib; chronic myeloid leukemia; tyrosine kinase inhibitor resistance; majormolecular response; deep molecular response."

Clinical • Chronic Myeloid Leukemia • Leukopenia • Neutropenia • Thrombocytopenia • ABL1 • BCR

Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study (ASH 2025) - P=N/A | "Patients received theTKI combine with low-dose chemotherapy (overembatinib, vincristine, prednisone and venetoclax) asinduction therapy, followed by 1-2 cycles of TKI combine with oral regimens (olverembatinib, venetoclax,and prednisone) as outpatient consolidation treatment. Then, a single infusion of murine-derived second-generation CD19-directed CAR T-cells (with a 4-1BB co-stimulatory domain) during first remission.Maintenance therapy included alternating administrations of vincristine, methotrexate, mercaptopurine,prednisone, venetoclax, and oral TKI. Intrathecal methotrexate (MTX), cytarabine, and dexamethasonewere administered for central nervous system (CNS) prophylaxis... Front-line CAR-T therapy as consolidation in newly diagnosed Ph⁺B-ALL patients is a safe andeffective regimen, resulting in deep remission without the need for intensive chemotherapy, and offeringhope for sustained remission.Key wordsAcute lymphoblastic leukemia, Front-line CAR-T,..."

Clinical • IO biomarker • P2 data • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • ABL1 • BCR

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) (ASH 2025) - P3 | "Induction therapy comprised 3 cycles of VD or VDP: vincristine1.4 mg/m2 (maximum 2 mg) on days (D) 1, 8, 15, and 22; dexamethasone 10 mg on D1–14, 5 mg on D15–21, and 2.5 mg on D22–28; and daunorubicin 25 mg/m2 (maximum 40 mg; 20 mg for patients ≥ 70 years)on D1–3. Consolidation alternated 3 cycles of high-dose methotrexate (1.0 g/m2, 1 day) with 3 cycles ofcytarabine (1,000 mg/m2 every 12 hours; 250 mg/m2 every 12 hours for patients > 60 years, 3 days).Maintenance therapy of mercaptopurine plus methotrexate and VP was alternated for 12 cycles atstandard dosages...The regimenextended the window for further treatment and demonstrated a favorable safety profile. (NCT06051409; HQP1351AG301)."

Clinical • P3 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Neutropenia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia • ABL1 • BCR • CDKN2A • CDKN2B • EBF1 • ETV6 • IKZF1 • PAX5

Asciminib for relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast crisis of chronic myeloid leukemia (LBC-CML) in Italy: A Campus ALL real life study (ASH 2025) - "Seven patients (37%) received combinationtherapy: one with imatinib (400 mg daily), five with ponatinib (30 mg daily), and one sequentially afterhigh-dose chemotherapy and radiotherapy.Daily asciminib doses in combination therapy ranged from 40 mg once daily (1 patient) to 40 mg twicedaily (6 patients). From September 2021 to April 2025, 19 patients (12 Ph+ ALL, 7 LBC-CML) received asciminib.Median age was 55 years (range 20–77) and 12 were male.Prior to asciminib, patients had received a median of 2 prior TKIs (range 1–3). Six patients had receivedBlinatumomab, 10 Inotuzumab, 8 had relapsed after allogeneic transplantation and 5 had undergoneCAR-T therapy.Asciminib was started in hematologic relapse in 11 patients, in 7 with MRD relapse/ recurrence, and in 1MRD-negative patient (the latter due to inacceptable toxicities during previous therapies). Centralnervous system involvement was observed in 2 patients.At the time of the analysis, median follow-up from asciminib..."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Hypertension • Leukemia • Musculoskeletal Diseases • Musculoskeletal Pain • Neutropenia • Thrombocytopenia • ABL1 • BCR

Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report (ASH 2025) - "All patients receivedTKIs+chemotherapy before transplantation and were stratified by pre-transplant TKIs exposure: 1/2G-TKIcohort (n=42, imatinib, nilotinib, flumatinib or dasatinib) versus olverembatinib (n=21, HQP1351), withbalanced baseline characteristics. This real-world analysis provides the first clinical evidence supporting the efficacy and safetyof olverembatinib in transplant-eligible BC-CML. Olverembatinib significantly enhances pre-transplantmolecular responses, compared to 1/2G-TKIs, associating with improved survival and reduced NRM inBC-CML patients receiving allo-HSCT. With a manageable safety profile, olverembatinib represents apromising bridging strategy prior to allo-HSCT, potentially redefining frontline management of BC-CML."

Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Thrombosis • Transplantation • ABL1 • ASXL1 • IKZF1 • RUNX1

Ponatinib alleviates CAR-T cell exhaustion and remodels the immune microenvironment: A promising combination strategy for relapsed/refractory b-ALL (ASH 2025) - P=N/A | "This study provides preclinical and preliminary clinical evidence that third-generation TKIs, particularlyponatinib, can effectively alleviate CAR-T cell exhaustion, promote memory phenotypes, and remodel theimmune microenvironment. Compared to dasatinib and olverembatinib, ponatinib uniquely enhanceseffector cytokine production and activates the IFN-γ pathway. These findings support ponatinib as apromising combinatorial agent with CAR-T therapy, offering a rational strategy for improving outcomes inpatients with T315I-mutated R/R B-ALL."

CAR T-Cell Therapy • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Immune Modulation • Immunology • Leukemia • CCR7 • CTLA4 • HAVCR2 • IFNG • IL7R • LAG3 • NR4A1 • PD-L1 • TCF7 • TGFB1 • TNFA

Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement (ASH 2025) - "MethodsPreclinical StudyTwo most common FGFR1 fusions of ZNF198::FGFR1, BCR::FGFR1were transfected into Ba/F3 cells andtreated with olverembatinib, ponatinib, and pemigatinib. ConclusionsOlverembatinib was highly effective and well tolerated in patients with MLN-FGFR1 in both preclinical andclinical settings. Combined chemotherapy was preferable in patients with BP disease, and allo-HSCTremained an important strategy for extending survival."

Preclinical • Bone Marrow Transplantation • Cardiovascular • Chronic Myeloid Leukemia • CNS Disorders • Eosinophilia • Hematological Malignancies • Hypertension • Infectious Disease • Myeloproliferative Neoplasm • Neutropenia • CASP3 • FGFR1 • RUNX1 • STAT3 • STAT5 • ZMYM2

Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia. (PubMed, Haematologica) - "Not available."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

The Efficacy and Safety of Olverembatinib Combined with Monoclonal Antibodies As Salvage Therapy for RR B ALL with ABL1 Fusion Gene Positive (ASH 2023) - "Recently, such pts have new hope with the wide application of a novel third-generation TKI Olverembatinib developed in China and Blinatumomab（CD19 antibody,BITE）and INOTUZUMAB OZOGAMICIN(CD22 antibody,Ino. For heavily treated RR ABL1+B ALL pts,including those after treatment with ponatinib and other TKICART and HSCT, Olverembatinib combined with monoclonal antibodies is effective and safe. In my cases, it is particularly noteworthy that one pts ,Ph like ALL with ABL1 FG, received Olverembatinib combination BITE and achieved a surprising response, so Olverembatinib may also be effective and safe for such pts. In addition, venetoclax may be used as a sensitizer for TKI or other antitumor drugs."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Transplantation • ABL1 • BCR • CD22

Treatment with Blinatumomab in Combination with Venetoclax for Mixed Phenotype Acute Leukemia (ASH 2023) - "Here, we present 6 patients with CD19-positive MPAL that are successfully treated with blinatumomab in combination with venetoclax and/or azacytidine in front line setting...The patient with BCR: : ABL1 received blinatumomab in combination with olverembatinib. Intrathecal (IT) chemotherapy with cytarabine and methotrexate was administered to central nervous system (CNS) as prophylaxis treatment... The results provide preliminary evidence of effective and safe treatment with blinatumomab and venetoclax combination as first-line therapy in MPAL resulting in the achievement of normal bone marrow function with less toxicity than using conventional chemotherapy."

Combination therapy • IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Neutropenia • Oncology • Thrombocytopenia • Transplantation • ABL1 • KMT2A